Prior notification of a concentration (Case M.11168 – WARBURG PINCUS / ADVENT INTERNATIONAL / BAXTER PHARMACEUTICAL SOLUTIONS AND BAXTER ONCOLOGY) Candidate case for simplified procedure (Text with EEA relevance) 2023/C 272/05
Date: 2023-08-01
Institutions: Directorate-General for Competition, European Commission
Subjects: contract, economic concentration, energy industry, financial services, health care, investment company, merger control, pharmaceutical industry, service, technology, telecommunications








C_2023272EN.01000701.xml










1.8.2023   


EN


Official Journal of the European Union


C 272/7






Prior notification of a concentration
(Case M.11168 – WARBURG PINCUS / ADVENT INTERNATIONAL / BAXTER PHARMACEUTICAL SOLUTIONS AND BAXTER ONCOLOGY)
Candidate case for simplified procedure
(Text with EEA relevance)
(2023/C 272/05)

1.   
On 25 July 2023, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1).
This notification concerns the following undertakings:






—


Warburg Pincus LLC and affiliated funds (‘Warburg Pincus’, USA),










—


Advent International Corporation and affiliated funds (‘Advent’, USA),










—


Baxter Pharmaceutical Solutions LLC (USA) and Baxter Oncology GmbH (Germany) (‘BPS’).




Warburg Pincus and Advent will acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint control of the whole of BPS.
The concentration is accomplished by way of purchase of shares.


2.   
The business activities of the undertakings concerned are the following:






—


Warburg Pincus is a global private equity firm. Its portfolio companies are active in a variety of sectors, including energy, financial services, healthcare and consumer, industrial and business services, and technology, media and telecommunications,










—


Advent is a private equity investor focusing on the acquisition of equity stakes and the management of investment funds in various sectors, including healthcare, industrial, technology, retail, consumer and leisure, and business and financial services,










—


BPS is Baxter International Inc.’s global pharmaceutical contract development and manufacturing business. It provides Contract Development and Manufacturing Organization services for Finished Dose Pharmaceuticals.






3.   
On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.
Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.


4.   
The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:
M.11168 – WARBURG PINCUS / ADVENT INTERNATIONAL / BAXTER PHARMACEUTICAL SOLUTIONS AND BAXTER ONCOLOGY
Observations can be sent to the Commission by email or by post. Please use the contact details below:
Email: COMP-MERGER-REGISTRY@ec.europa.eu
Postal address:





European Commission




Directorate-General for Competition




Merger Registry




1049 Bruxelles/Brussel




BELGIQUE/BELGIË







(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

(2)  OJ C 366, 14.12.2013, p. 5.